Tri Locum Partners LP Sells 420,772 Shares of Evolus, Inc. $EOLS

Key Points

• Tri Locum Partners LP has reduced its holdings in Evolus, Inc. by 56.7%, selling 420,772 shares and now owning 321,802 shares, which constitutes 2.0% of its portfolio.
• Internal movements include Director Albert G. White III purchasing 20,000 shares while insider David Moatazedi sold 111,323 shares, indicating a mixed sentiment among company insiders.
• Evolus has a current market capitalization of $490.27 million with a 1-year low of $5.71 and a high of $17.82, while analysts provide a consensus rating of "Moderate Buy" with an average price target of $21.25.

Tri Locum Partners LP decreased its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 56.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 321,802 shares of the company's stock after selling 420,772 shares during the quarter. Evolus accounts for approximately 2.0% of Tri Locum Partners LP's holdings, making the stock its 17th biggest holding. Tri Locum Partners LP owned 0.50% of Evolus worth $3,871,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. AlphaQuest LLC acquired a new position in shares of Evolus in the 1st quarter valued at $39,000. IFP Advisors Inc increased its position in shares of Evolus by 99.0% during the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock worth $113,000 after purchasing an additional 4,691 shares in the last quarter. Rafferty Asset Management LLC acquired a new stake in shares of Evolus during the 4th quarter worth about $115,000. Man Group plc acquired a new stake in shares of Evolus during the 4th quarter worth about $121,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Evolus during the 1st quarter worth about $151,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Insider Activity at Evolus

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $7.51, for a total transaction of $42,972.22. Following the sale, the chief marketing officer owned 89,949 shares of the company's stock, valued at $675,516.99. This represents a 5.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Albert G. White III acquired 20,000 shares of the firm's stock in a transaction on Monday, June 9th. The shares were bought at an average cost of $9.45 per share, for a total transaction of $189,000.00. Following the acquisition, the director owned 50,378 shares in the company, valued at approximately $476,072.10. The trade was a 65.84% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 133,627 shares of company stock worth $1,325,764 in the last quarter. Insiders own 5.90% of the company's stock.

Evolus Price Performance

NASDAQ:EOLS traded up $0.11 during mid-day trading on Friday, reaching $7.63. 472,060 shares of the company were exchanged, compared to its average volume of 2,259,618. Evolus, Inc. has a 12 month low of $5.71 and a 12 month high of $17.82. The company has a fifty day moving average of $8.43 and a 200 day moving average of $10.41. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00. The stock has a market cap of $493.51 million, a PE ratio of -7.79 and a beta of 1.12.

Analyst Upgrades and Downgrades

EOLS has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Needham & Company LLC reiterated a "hold" rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. HC Wainwright dropped their target price on shares of Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Finally, BTIG Research dropped their target price on shares of Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $21.25.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.